14-day Premium Trial Subscription Try For FreeTry Free
$4.45
-0.0300 (-0.670%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $4.03 $5.16 Friday, 3rd May 2024 BCRX stock ended at $4.45. This is 0.670% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.66% from a day low at $4.42 to a day high of $4.67.
90 days $4.03 $6.35
52 weeks $4.03 $8.96

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Nov 05, 2021 $11.55 $12.83 $11.53 $12.41 4 685 127
Nov 04, 2021 $12.16 $12.27 $11.52 $11.61 6 445 424
Nov 03, 2021 $13.53 $13.97 $12.13 $12.40 12 730 545
Nov 02, 2021 $15.31 $15.48 $14.99 $15.14 2 371 424
Nov 01, 2021 $15.07 $15.35 $14.93 $15.31 2 151 186
Oct 29, 2021 $15.24 $15.40 $14.84 $14.93 1 655 173
Oct 28, 2021 $14.98 $15.27 $14.82 $15.24 1 689 817
Oct 27, 2021 $15.47 $15.55 $14.91 $14.93 2 441 851
Oct 26, 2021 $15.67 $15.77 $15.34 $15.38 1 604 439
Oct 25, 2021 $14.71 $15.49 $14.61 $15.46 2 608 690
Oct 22, 2021 $14.60 $14.77 $14.34 $14.70 1 522 581
Oct 21, 2021 $14.33 $14.70 $14.28 $14.61 1 410 819
Oct 20, 2021 $14.97 $15.08 $14.31 $14.33 2 405 177
Oct 19, 2021 $15.00 $15.28 $14.76 $15.04 1 868 279
Oct 18, 2021 $15.10 $15.24 $14.91 $14.92 3 064 200
Oct 15, 2021 $15.44 $15.54 $15.12 $15.13 1 969 044
Oct 14, 2021 $15.13 $15.59 $15.13 $15.45 2 689 105
Oct 13, 2021 $14.82 $15.01 $14.59 $14.99 2 517 297
Oct 12, 2021 $14.50 $15.00 $14.40 $14.71 2 192 097
Oct 11, 2021 $14.49 $14.61 $14.35 $14.42 1 689 326
Oct 08, 2021 $14.01 $14.48 $13.72 $14.46 2 343 638
Oct 07, 2021 $13.60 $13.96 $13.54 $13.96 1 962 684
Oct 06, 2021 $13.49 $13.69 $13.29 $13.53 2 179 961
Oct 05, 2021 $13.35 $13.79 $13.35 $13.73 1 833 024
Oct 04, 2021 $13.51 $13.70 $13.10 $13.31 3 177 103
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Golden Star

Ticker Date Change Price
BSCQ Apr 30 0.393% $19.09
EQC Apr 30 1.76% $18.72
HRB Apr 30 1.69% $47.23
REG Apr 30 1.35% $59.22
INGR Apr 30 0.576% $114.59
BSJP Apr 29 0.175% $22.91
LYG Apr 29 0.781% $2.56
ORA Apr 29 3.46% $64.48
DHT Apr 24 4.34% $11.28
LPLA Apr 19 2.62% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT